Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started
My Medicine

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Cancer Health Center

Font Size

Sutent, Tykerb May Curb Liver Cancer

Studies Show Drugs May Help Treat Advanced Liver Cancer
WebMD Health News
Reviewed by Louise Chang, MD

April 16, 2008 (San Diego) -- Two anticancer drugs show promise for treating people with advanced liver cancer, one of the deadliest types of cancers.

One drug, Sutent, stopped tumor growth and spread in about half of people with advanced liver cancer.

In a second study, a once-a-day pill called Tykerb halted tumor growth in about one-third of patients.

People with advanced liver cancer have very few options, says Andrew X. Zhu, MD, PhD, director of liver cancer research at Massachusetts General Hospital Cancer Center in Boston.

Nexavar is the only medication that's been shown to extend their lives, he says. It was approved by the FDA in November after a large study showed people with advanced liver cancer given Nexavar lived about three months longer than those given a placebo: 10.7 months vs. 7.9 months.

Enter Sutent, which puts the brakes on the growth of tumor-feeding blood vessels and deprives tumor cells of blood and nutrients needed for growth.

It is part of a class of drugs called tyrosine kinase inhibitors. It's already approved to treat advanced kidney cancer and recalcitrant gastrointestinal stromal tumors (GIST).

Sutent Halts Tumor Growth

The study involved 34 patients with advanced liver cancer. They took one Sutent pill a day for four weeks. Then they took a drug holiday for two weeks and repeated the cycle.

The findings were presented here at the annual meeting of the American Association for Cancer research.

By 12 weeks after starting treatment, the tumor shrank in only one patient. But 17 patients had stable disease -- "that is, tumor growth had stopped and they were doing well clinically," Zhu says.

Patients lived an average of 10 months.

Importantly, molecular markers showed clear evidence that the drug was associated with antitumor activity, Zhu says.

The treatment was safe, he adds. Common side effects included elevated liver enzymes, low levels of certain blood cells, and fatigue.

Christopher Willett, MD, head of radiation oncology at Duke University in Durham, N.C., tells WebMD that the findings are "preliminary, but encouraging."

The fact that there was evidence of changes in molecular markers that signal better outcome is particularly noteworthy, Willett says.

Today on WebMD

Colorectal cancer cells
New! I AM Not Cancer Facebook Group
Lung cancer xray
See it in pictures, plus read the facts.
sauteed cherry tomatoes
Fight cancer one plate at a time.
Ovarian cancer illustration
Real Cancer Perspectives
Jennifer Goodman Linn self-portrait
what is your cancer risk
colorectal cancer treatment advances
breast cancer overview slideshow
prostate cancer overview
lung cancer overview slideshow
ovarian cancer overview slideshow
Actor Michael Douglas